Iwicki Mark T
SEC-identified person · CIK 1415537 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Q32 Bio Inc. QTTB | Director | filed 2024 - 2026 |
| Inhibikase Therapeutics, Inc. IKT | Director · Chief Executive Officer | filed 2025 - 2026 |
| Merus N.V. MRUS | Director | filed 2020 - 2025 |
| Akero Therapeutics, Inc. AKRO | Director | filed 2019 - 2025 |
| Kala Pharmaceuticals, Inc. KALA | Director · Chief Executive Officer | filed 2017 - 2025 |
| Third Harmonic Bio, Inc. THRD | Director | filed 2022 - 2025 |
| Jade Biosciences, Inc. JBIO | Director | filed 2021 - 2024 |
| Ruthigen, Inc. RTGN | Director | filed 2015 - 2021 |
| Aimmune Therapeutics, Inc. AIMT | Director | filed 2015 - 2020 |
| Sepracor INC /DE/ SEPR | EVP & Chief Commercial Officer | filed 2007 - 2009 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.